Literature DB >> 20437852

Selective sentinel lymph node biopsy and primary systemic therapy in breast cancer.

Antonio Piñiero1, Julia Giménez, Sergi Vidal-Sicart, Mattia Intra.   

Abstract

AIMS AND
BACKGROUND: Sentinel lymph node biopsy has become an ordinary method for breast cancer staging. Neoadjuvant chemotherapy has been considered one of the contraindications for sentinel lymph node biopsy due to potential secondary fibrosis and lymphatic distortion. Timing and influence on sentinel lymph node biopsy result by primary systemic therapy are current and controversial topics. METHODS AND STUDY
DESIGN: The experience in the medical literature is reviewed. A search was performed in the following databases: Medline (through Pubmed), EMBASE, Tripdatabase and Cochrane Library, between January 1998 and December 2008. RESULTS AND
CONCLUSIONS: After analyzing the conclusions from 42 series and waiting for the end of related prospective trials, it could be concluded that sentinel lymph node biopsy is a useful diagnostic tool that should be integrated in the algorithm for the management of breast cancer patients when primary systemic therapy is needed.

Entities:  

Mesh:

Year:  2010        PMID: 20437852     DOI: 10.1177/030089161009600103

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  1 in total

1.  Sentinel node mapping for breast cancer: current situation.

Authors:  Sergi Vidal-Sicart; Renato Valdés Olmos
Journal:  J Oncol       Date:  2012-08-15       Impact factor: 4.375

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.